Financing follows Torres's CrossBridge Bio acquisition by Eli Lilly and supports translation of ARTAN Bio's programmable approach to mutation-driven aging biology

继礼来公司收购Torres旗下的CrossBridge Bio之后，此次融资将支持ARTAN Bio将其可编程方法转化为针对突变驱动衰老生物学的研究成果。

ST. PETERSBURG, Fla.

佛罗里达州圣彼得堡

,

，

July 1, 2026

2026年7月1日

/PRNewswire/ --

/美通社/ --

ARTAN Bio

ARTAN生物

, a longevity biotechnology company based in St. Petersburg, Florida, today announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D., following his role as Co-Founder and Chief Executive Officer of CrossBridge Bio through its acquisition by Eli Lilly. The financing will support advancement of ARTAN Bio's proprietary mutation-specific codon suppression platform toward first-in-human development..

总部位于佛罗里达州圣彼得堡的长寿生物技术公司ARTAN Bio今日宣布，完成由该公司联合创始人Michael Torres博士领投的100万美元种子轮融资。此前，Michael Torres曾担任CrossBridge Bio的联合创始人兼首席执行官，直至该公司被礼来（Eli Lilly）收购。本轮融资将用于推动ARTAN Bio专有的突变特异性密码子抑制平台向首次人体试验阶段迈进。

In conjunction with the financing, ARTAN Bio also announced the appointment of Brian Bodemann as Chief Executive Officer. Bodemann brings a research-grade command of the science together with broad exposure across life-science commercial markets — positioning him to bridge ARTAN Bio's platform with the indications and partners it can ultimately serve.

伴随着此次融资，ARTAN Bio还宣布任命Brian Bodemann为首席执行官。Bodemann不仅具备科研级别的专业知识，还在生命科学商业市场拥有广泛的经验，这使他能够将ARTAN Bio的平台与其最终可以服务的适应症和合作伙伴连接起来。

Co-founder Anthony Schwartz, Ph.D., will transition from Chief Executive Officer to Chief Operating Officer, strengthening the company's operational and scientific leadership as it advances the platform through the next stage of translational development..

联合创始人安东尼·施瓦茨博士将从首席执行官转任首席运营官，以加强公司在推进平台进入下一阶段转化发展过程中的运营和科学领导力。

Advancing a Mutation-Specific Platform Toward Human Studies

推进突变特异性平台向人体研究迈进

ARTAN Bio's lead platform is built around an engineered suppressor tRNA system designed to restore protein translation in cells harboring disease-causing nonsense mutations. The seed investment will support the transition from preclinical research toward first-in-human development, including IND-enabling studies, manufacturing scale-up, and regulatory preparation..

ARTAN Bio 的核心平台围绕一种工程化的抑制性 tRNA 系统构建，旨在恢复携带致病性无义突变的细胞中的蛋白质翻译。这笔种子投资将支持公司从临床前研究向首次人体试验开发的过渡，包括开展新药临床试验申请（IND）所需的研究、生产规模扩大以及监管申报准备工作。

Nonsense mutations are genetic errors that create premature stop signals during protein translation, preventing production of full-length functional proteins. These mutations are implicated across a wide range of genetic and aging-related diseases. ARTAN Bio's mutation-specific approach is designed to address disease at the level of the underlying genetic lesion, with potential applications across multiple indications where restoration of protein function could be therapeutically meaningful..

无义突变是指在蛋白质翻译过程中产生提前终止信号的遗传错误，从而阻止全长功能蛋白的生成。这些突变与多种遗传性疾病及衰老相关疾病有关。ARTAN Bio 采用的突变特异性方法旨在从根本遗传损伤层面治疗疾病，在多个适应症中具有潜在应用价值，因为在这些适应症中，恢复蛋白质功能可能具有治疗意义。

Executive Commentary

高管评论

'After building CrossBridge Bio through its acquisition by Eli Lilly, my thesis as a CEO, scientist, and company builder is to back science with the potential to become category-defining,' said Michael Torres, Ph.D., Co-Founder and Chief Scientific Officer of ARTAN Bio. 'That is what I believe ARTAN Bio can be.

“在通过礼来公司（Eli Lilly）的收购打造CrossBridge Bio之后，我作为首席执行官、科学家和企业建设者的核心理念是，支持那些有潜力成为品类定义者的科学。我相信ARTAN Bio正是这样的企业。”ARTAN Bio联合创始人兼首席科学官Michael Torres博士表示。

The platform sits at the intersection of genetics, aging biology, and programmable medicines, with the potential to address disease at the level of the underlying mutation. I am personally investing because I believe the science is differentiated, the opportunity is significant, and the team is ready to move this toward patients.'.

该平台处于遗传学、衰老生物学和可编程药物领域的交叉点，有望在根本突变层面解决疾病问题。我之所以进行个人投资，是因为我相信其科学原理具有独特性，市场机遇巨大，且团队已准备好推动该疗法惠及患者。

'Bringing Brian on as CEO positions ARTAN Bio for the clinical, operational, and partnership work ahead,' said Anthony Schwartz, Ph.D., Co-Founder and Chief Operating Officer of ARTAN Bio. 'My focus as COO will be on disciplined execution as we move from preclinical research toward human studies. The science has reached the point where disciplined translation is the right next step, and this financing gives us the ability to advance that work with urgency and rigor.'.

ARTAN Bio联合创始人兼首席运营官Anthony Schwartz博士表示：“聘请Brian担任首席执行官，使ARTAN Bio能够为接下来的临床、运营及合作伙伴工作做好定位。作为首席运营官，我将专注于在我们从临床前研究向人体研究推进的过程中进行严谨的执行。科学进展已达到这样一个阶段：严谨的转化是下一步的正确选择，而此次融资使我们能够以紧迫感和严谨性推进这项工作。”

'What drew me to ARTAN Bio is that the science is real and the aperture is wide — one programmable mechanism for restoring proteins that nonsense mutations switch off, with relevance across genetic and aging-driven disease,' said Brian Bodemann, incoming Chief Executive Officer. 'My focus is to translate that platform into the indications and partnerships where it matters most.

“吸引我加入ARTAN Bio的是，其科学基础扎实且应用前景广阔——它提供了一种可编程机制，用于恢复因无义突变而失活的蛋白质，在遗传性疾病和衰老相关疾病领域具有广泛的相关性。”即将上任的首席执行官Brian Bodemann表示。“我的重点是将这一平台转化为在最关键适应症和合作伙伴关系中的实际应用。”

Michael and Anthony built something differentiated; the work now is to prove what it can become.'.

迈克尔和安东尼打造了一款具有差异化优势的产品；当下的任务是证明它未来能够发展成什么样子。

About ARTAN Bio

关于 ARTAN Bio

ARTAN Bio is a longevity biotechnology company headquartered in St. Petersburg, Florida, at

ARTAN Bio 是一家总部位于佛罗里达州圣彼得堡的长寿生物技术公司，

spARK Labs

spARK 实验室

by

由

ARK Invest

方舟投资

. The company is developing mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions caused by nonsense mutations. ARTAN Bio's platform is designed to deliver engineered suppressor systems through established delivery modalities to restore protein function in affected cells..

该公司正在开发针对特定突变的密码子抑制技术，以应对由无义突变引起的遗传性疾病和衰老相关病症。ARTAN Bio的平台旨在通过成熟的递送方式传递工程化的抑制系统，从而在受影响的细胞中恢复蛋白质功能。

About the VITARNA

关于 VITARNA

Token

令牌

$VITARNA

$VITARNA

tokens represent fractions of governance rights over the Mutation-Specific Codon Suppression for Aging and Longevity IP-NFT. The primary issuance is offered via the

代币代表对“针对衰老与长寿的突变特异性密码子抑制”IP-NFT 的部分治理权。首次发行通过以下渠道提供：

Molecule AG

分子股份公司

platform.

平台。

Token

令牌

holders participate in governance decisions including research prioritization, IP licensing strategy, and allocation of research funds, a model intended to broaden participation in early-stage biotechnology and align scientific progress with community stakeholders.

持有者参与治理决策，包括研究优先级排序、知识产权许可策略以及研究资金的分配，该模式旨在扩大对早期生物技术领域的参与，并使科学进步与社区利益相关方保持一致。

About VitaDAO

关于 VitaDAO

VitaDAO

VitaDAO

is a

是一个

decentralized

去中心化

autonomous organization dedicated to funding and advancing longevity science research. VitaDAO supports early-stage research projects through its IP-NFT model, enabling community participation in the governance of longevity IP.

致力于资助和推进长寿科学研究的自治组织。VitaDAO 通过其 IP-NFT 模式支持早期研究项目，使社区能够参与长寿知识产权的治理。

This press release is for informational purposes only. VITARNA tokens are governance instruments, and this release does not constitute an offer or solicitation.

本新闻稿仅用于提供信息。VITARNA代币是治理工具，本新闻稿不构成要约或招揽。

SOURCE ARTAN BIO

来源：阿尔坦生物

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示